Erbitux Being TAILOR-Made For Chinese First-Line mCRC Market, But Brand Recognition Is Merck's Real Goal
Executive Summary
Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux (cetuximab) have received a boost with a Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.